Alkem Laboratories launches affordable semaglutide injection in India
By: IPP Bureau
Last updated : March 26, 2026 2:29 pm
Alkem’s semaglutide comes in a pre-filled disposable injection pen containing four doses for a month, priced at Rs. 1,800
Alkem Laboratories hasannounced the launch of its semaglutide injection in India under the brand names “Semasize,” “Obesema,” and “Hepaglide.” The therapy, administered once weekly via subcutaneous injection, will now be available at a cost starting Rs. 450 per week.
Alkem’s semaglutide comes in a pre-filled disposable injection pen containing four doses for a month, priced at Rs. 1,800. For patients requiring higher maintenance doses, the company is also offering a reusable injection pen, allowing users to replace only the medication cartridge instead of buying a new pen each time—reducing costs and supporting better adherence.
The launch follows approval from the Drug Controller General of India (DCGI) for the treatment of type 2 diabetes mellitus and chronic weight management as an adjunct to diet and exercise, based on Phase 3 clinical trials conducted in India. Semaglutide is a prescription product and should be administered under medical supervision.
Commenting on the launch, Vikas Gupta, CEO of Alkem, said, "We believe therapeutic advancements must translate into real-world access to create a lasting impact. With the launch of our indigenously-developed semaglutide, we are bringing a high-quality and affordable option to market, empowering healthcare practitioners to offer this therapy to more deserving patients.
"Through our strong distribution network and patient-friendly devices, we aim to make the product accessible to a larger section of the population and contribute to better overall healthcare outcomes."
With this launch, Alkem aims to make semaglutide therapy more accessible and affordable, potentially transforming care for millions of patients managing diabetes and weight challenges in India.